Valeant Pharmaceuticals to divest Sprout Pharmaceuticals in strategic move
Valeant Pharmaceuticals International has announced a significant transaction involving the sale of Sprout Pharmaceuticals back to its original owners. This strategic divestiture includes a deal where Valeant will receive a 6% royalty on global sales of Sprout’s female libido drug, Addyi (flibanserin), for 18 months following the closure of the sale. Background of the Acquisition […]